Incidence of and Risk Factors for Cataract in Anterior Uveitis.
George N Papaliodis, Bernard A Rosner, Kurt A Dreger, Tonetta D Fitzgerald, Pichaporn Artornsombudh, Srishti Kothari, Sapna S Gangaputra, Grace A Levy-Clarke, Robert B Nussenblatt, James T Rosenbaum, H Nida Sen, Eric B Suhler, Jennifer E Thorne, Nirali P Bhatt, C Stephen Foster, Douglas A Jabs, Clara M Pak, Gui-Shuang Ying, John H Kempen
Summary
Cataract developed in 507 eyes (54/1000 eye-years, 95% CI 49-59).
Abstract
PURPOSE
To estimate the incidence/risk factors for cataract in noninfectious anterior uveitis.
DESIGN
Retrospective multicenter cohort study (6 US tertiary uveitis sites, 1978-2010).
METHODS
Data were harvested by trained expert reviewers, using protocol-driven review of experts' charts. We studied cataract incidence-newly reduced visual acuity worse than 20/40 attributed to cataract; or incident cataract surgery-in 3923 eyes of 2567 patients with anterior uveitis.
RESULTS
Cataract developed in 507 eyes (54/1000 eye-years, 95% CI 49-59). Time-updated risk factors associated with cataract included older age (≥65 vs 2-fold higher cataract risk in eyes with anterior chamber cell grades 0.5+ or lower but was not associated with higher cataract risk in the presence of anterior chamber cells of grade 1+ or higher.
CONCLUSIONS
Cataract complicates anterior uveitis in ∼5.4/100 eye-years. Several fixed and modifiable risk factors were identified, yielding a point system to guide cataract risk minimization. Topical corticosteroids only were associated with increased cataract risk when anterior chamber cells were absent or minimally present, suggesting their use to treat active inflammation (which itself is cataractogenic) does not cause a net increase in cataract incidence.
More by George N Papaliodis
View full profile →Chemical Burns of the Eye: The Role of Retinal Injury and New Therapeutic Possibilities.
Restoration of Vision in Severe, Cicatricial, Ocular Surface Disease With the Boston Keratoprosthesis Type II.
A 70-Year-Old Man With Pain and a Creamy Elevated Lesion After Transscleral Cyclophotocoagulation.
Top Research in Epidemiology & Genetics
Browse all →The Risks and Benefits of Myopia Control.
Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).
Neuroprotective strategies for retinal disease.
In the Knowledge Library
Discussion
Comments and discussion will appear here in a future update.